We use our own and third party cookies to offer you our services, customize and analyze your browsing and show you advertising related to your preferences. By continuing to browse, we consider that you accept its use. You can change the settings and get more information in the
Current lines of research are mainly focused on new, longer-lasting intravitreal treatments to prevent the primary chronic complication of the disease –diabetic macular oedema. The present treatment involves several monthly injections that are repeated over time. New sustained-release treatments and devices should help reduce the number of injections and hospital visits.
On the other hand, researchers are also studying individualising treatments to each patient. That is, by using information obtained from photographs of the eye fundus or scans of the retina, they are trying to determine which cases are more severe and may require more treatment than others before even starting therapy. In the same way, it is also being studied from samples of each case, for example, the aqueous humor, some molecules and knowing what will be the best treatment for each case.
Together, these studies aim to discover biomarkers that help improve our understanding of the disease.